Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of SYN 005 for the treatment of pertussis

Trial Profile

Phase I trial of SYN 005 for the treatment of pertussis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SYN 005 (Primary)
  • Indications Pertussis
  • Focus Adverse reactions
  • Sponsors Synthetic Biologics
  • Most Recent Events

    • 16 Mar 2015 According to Synthetic Biologics media release, orphan drug designation has been granted to SYN 005, by the US FDA
    • 08 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top